News stories about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.7410914286667 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Several brokerages have recently weighed in on SBPH. JMP Securities began coverage on shares of Spring Bank Pharmaceuticals in a research note on Friday, May 19th. They issued a “market perform” rating and a $20.00 price objective on the stock. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Chardan Capital lowered their price objective on shares of Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, August 1st. ValuEngine cut shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Cantor Fitzgerald began coverage on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They issued an “overweight” rating and a $29.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $26.33.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at 12.67 on Friday. The stock’s market capitalization is $160.87 million. Spring Bank Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $16.97. The company has a 50-day moving average of $13.75 and a 200 day moving average of $11.60.

In other news, Director Kurt M. Eichler purchased 76,923 shares of the firm’s stock in a transaction dated Tuesday, June 27th. The stock was bought at an average price of $13.00 per share, with a total value of $999,999.00. Following the acquisition, the director now directly owns 582,533 shares of the company’s stock, valued at $7,572,929. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Arkowitz purchased 2,500 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was purchased at an average cost of $12.24 per share, with a total value of $30,600.00. Following the acquisition, the director now directly owns 17,086 shares in the company, valued at $209,132.64. The disclosure for this purchase can be found here. Insiders bought a total of 81,423 shares of company stock valued at $1,055,319 in the last three months. 17.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/26/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-spring-bank-pharmaceuticals-sbph-share-price.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.